12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Selumetinib: Phase II data

An open-label, U.S. Phase II trial in 41 evaluable patients with locally advanced or metastatic pancreatic cancer showed that once-daily 100 mg oral selumetinib plus erlotinib as second-line treatment led to an estimated median OS of 7.5 months and median PFS of 2.6 months. The disease control rate (DCR) was 51%, with 21 cases of...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >